Global News

Koch Institute receives $1M from Takeda to support immuno-oncology research

Friday, February 10, 2017

Takeda Pharmaceutical and the Koch Institute for Integrative Cancer Research at MIT jointly announced that Takeda will support groundbreaking science in immuno-oncology at the Koch Institute. Over the next two years, the $1 million gift will help to build upon the research currently being conducted by the Institute to investigate the role of the immune response in cancer and develop potential novel treatments.

[Read More]

ERT launched refreshed eCOA technology environment

Friday, February 10, 2017

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, has announced the launch of its refreshed eCOA technology environment, which dramatically simplifies the implementation and management of trials that require collection of Clinical Outcomes Assessments.

[Read More]

FDA approves Amgen’s Parsabiv for secondary hyperparathyroidism

Thursday, February 9, 2017

Amgen has announced that the FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis healthcare team three times a week at the end of the hemodialysis session.

[Read More]

Acorda announces positive phase III CVT-301 results for Parkinson’s

Thursday, February 9, 2017

Acorda Therapeutics has announced phase III clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods in people with Parkinson’s disease taking an oral carbidopa/levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms.

[Read More]

Novozymes, Riffyn partner for experiment design and data analytics

Wednesday, February 8, 2017

Riffyn, a provider of visual design and data analytics software, announces the formation of a multiyear partnership with Novozymes to deploy and develop Riffyn’s cloud-based software for experiment design and data analytics. Riffyn’s Software-as-a-Service (SaaS) will be implemented progressively across Novozymes’ 1000-person global R&D organization to help support accelerated product development.

[Read More]

Report: Global clinical trial service market will reach $64B by 2020

Wednesday, February 8, 2017

Research and Markets research forecasts that the global clinical trial service market will likely reach more than $64 billion by 2020, up from $38.4 billion at present, representing a CAGR of 9% between 2015 and 2020. By 2020 the average clinical trial outsourcing penetration will likely reach around 72%. In other words, by then close to three fourths of clinical trials will likely be performed by professional CROs.

[Read More]